Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Gynecologic Oncology|January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2016
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology|September 22, 2016
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineAlexi A Wright, Kari Bohlke, Deborah K Armstrong, et al.
Gynecologic Oncology|July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survivalCasey M Cosgrove, David E Cohn, Heather Hampel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 2, 2020
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group studyDana Chase, Helen Q Huang, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Gynecologic Oncology|January 4, 2021
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patientsHeather Hampel, Rachel Pearlman, Albert de la Chapelle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2025
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline UpdateStéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial CancerMarcus E Randall, Virginia Filiaci, D Scott McMeekin, et al.
Pageof 16